Syphilis vaccine development: Aligning vaccine design with manufacturing requirements

Simple item page
dc.contributor.authorWaugh, Sean
dc.contributor.authorCameron, Caroline E.
dc.date.accessioned2026-05-07T17:31:19Z
dc.date.available2026-05-07T17:31:19Z
dc.date.issued2024
dc.description.abstractSyphilis, caused by Treponema pallidum subsp. pallidum, is a global health concern with increasing rates worldwide. Current prevention strategies, including screen-and-treat approaches, are not sufficient to resolve rising infection rates, emphasizing the need for a vaccine. Developing a syphilis vaccine necessitates a range of cross-disciplinary considerations, including essential disease-specific protection, technical requirements, economic feasibility, manufacturing constraints, public acceptance, equitable vaccine access, alignment with global public vaccination programs, and identification of essential populations to be vaccinated to achieve herd immunity. Central to syphilis vaccine development is prioritization of global vaccine availability, including access in low- to middle-income settings. Various vaccine platforms, including subunit, virus-like particle (VLP), mRNA, and outer membrane vesicle (OMV) vaccines, present both advantages and challenges. The proactive consideration of both manufacturing feasibility and efficacy throughout the pre-clinical research and development stages is essential for producing an efficacious, inexpensive, and scalable syphilis vaccine to address the growing global health burden caused by this disease.
dc.description.reviewstatusReviewed
dc.description.scholarlevelFaculty
dc.description.sponsorshipPrimary research reported in this commentary was supported by grants [R37AI051334]; [U19AI144133] and [1U01AI182035] from the National Institute of Allergy and Infectious Disease, National Institutes of Health and award [52345] from Open Philanthropy to CEC. SW is the recipient of a CIHR Canada Graduate Scholarship-Doctoral [CGS-D].
dc.identifier.citationWaugh, S., & Cameron, C. E. (2024). Syphilis vaccine development: Aligning vaccine design with manufacturing requirements. Human Vaccines & Immunotherapeutics, 20(1), 2399915. https://doi.org/10.1080/21645515.2024.2399915
dc.identifier.urihttps://doi.org/10.1080/21645515.2024.2399915
dc.identifier.urihttps://hdl.handle.net/1828/23855
dc.language.isoen
dc.publisherHuman Vaccines & Immunotherapeutics
dc.rightsCC BY-NC
dc.rights.urihttp://creativecommons.org/licenses/by-nc/4.0/
dc.subjectsyphilis
dc.subjectvaccine
dc.subjectTreponema pallidum
dc.subjectvaccine manufacturing
dc.subjectSexual and Reproductive Health and Rights (SRHR) Aspiration Research Cluster
dc.subject.departmentDepartment of Biochemistry and Microbiology
dc.titleSyphilis vaccine development: Aligning vaccine design with manufacturing requirements
dc.typeArticle

Files

Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
waugh_humVaccinImmunother_2024.pdf
Size:
518.26 KB
Format:
Adobe Portable Document Format
Download

Collections

SRHR Aspiration Research Cluster Publications
 
University of Victoria Libraries

We acknowledge and respect the Lək̓ʷəŋən (Songhees and Esquimalt) Peoples on whose territory the university stands, and the Lək̓ʷəŋən and W̱SÁNEĆ Peoples whose historical relationships with the land continue to this day.